ENDOTECH @ GISE 2017 – VISIT OUR BOOTH # 48
MILANO – MICO CONGRESS CENTRE
OCTOBER 10-13 2017
TOGETHER WITH OUR PARTNERS WE WILL PRESENT:
Sep 12, 2017
NASDAQ, TSX: NVCN
VANCOUVER, Sept. 12, 2017 /CNW/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today provided an update on the study progress and clinical performance of the TiaraTM valve, a self-expanding mitral bioprosthesis for transcatheter implantation in patients with Mitral Regurgitation (“MR”), one of the most prevalent valvular heart diseases in western countries. MR is often severe and can lead to heart failure and death.